Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

73.05 -0.08 (-0.11%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 Next >

Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% ↗

November 27, 2025

Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.

Via The Motley Fool

Topics Regulatory Compliance

Why This Private Equity-Style Fund Just Bet $17 Million on Lumen Technologies Stock ↗

November 27, 2025

One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds.

Via The Motley Fool

Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge ↗

November 27, 2025

This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline.

Via The Motley Fool

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Preview: Mirum Pharmaceuticals's Earnings ↗

May 06, 2025

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views ↗

November 13, 2024

Via Benzinga

What Analysts Are Saying About Mirum Pharmaceuticals Stock ↗

November 05, 2025

Via Benzinga

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Presents a Compelling Growth Momentum and Technical Setup ↗

October 18, 2025

Mirum Pharmaceuticals (MIRM) shows strong revenue growth and a positive technical setup, presenting a compelling case for momentum investors seeking breakout opportunities.

Via Chartmill

8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know ↗

October 16, 2025

Via Benzinga

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Combines Strong Growth Momentum with Bullish Technical Setup ↗

September 27, 2025

Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout.

Via Chartmill

This Riot Platforms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 24, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Earnings Outlook For Mirum Pharmaceuticals ↗

November 11, 2024

Via Benzinga

Analyst Expectations For Mirum Pharmaceuticals's Future ↗

October 11, 2024

Via Benzinga

Demystifying Mirum Pharmaceuticals: Insights From 6 Analyst Reviews ↗

September 12, 2025

Via Benzinga

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows High Growth Momentum and Technical Breakout Potential ↗

September 05, 2025

Mirum Pharmaceuticals (MIRM) shows strong growth momentum with 62% revenue growth and a bullish technical breakout pattern, making it a top biotech stock to watch.

Via Chartmill

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Screens as a High-Growth Momentum Stock Using Minervini Trend Template ↗

August 30, 2025

MIRUM Pharmaceuticals (MIRM) is a high-growth stock exhibiting a strong technical uptrend and robust revenue growth, making it a standout candidate for momentum investors.

Via Chartmill

Deep Dive Into Mirum Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗

August 08, 2025

Via Benzinga

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Surpasses Q2 2025 Estimates with Strong Revenue Growth and Raised Guidance ↗

August 06, 2025

Mirum Pharmaceuticals beats Q2 2025 estimates with $127.8M revenue, narrows losses, and raises full-year guidance. Stock surges 8.6% post-earnings.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 06, 2025

Via Benzinga

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Fits Minervini’s Trend Template with Strong Growth Momentum ↗

August 06, 2025

Mirum Pharmaceuticals (MIRM) fits Mark Minervini's trend-following strategy with strong technicals, revenue growth, and breakout potential. A high-growth momentum stock worth watching.

Via Chartmill

Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock ↗

May 09, 2025

Via Benzinga

FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish ↗

April 14, 2025

Livmarli tablets will be available in June through Mirum Access Plus pharmacy.

Via Stocktwits

FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol ↗

February 21, 2025

Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.

Via Benzinga

We Tested Top Stocks; Here’s What’s Best For Your Money ↗

November 10, 2024

Discover the top-performing stocks with our analysis. In this video, we dive into the Bollinger Band Squeeze strategy while scanning for opportunities.

Via Talk Markets

MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Beats Revenue for Q2 2024 ↗

August 07, 2024

MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

June 18, 2024

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.